Neuronetics (NASDAQ:STIM) Releases Earnings Results, Beats Estimates By $0.01 EPS

Posted by Geri Gentry on May 5th, 2026

Neuronetics (NASDAQ:STIM – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01, FiscalAI reports. Neuronetics had a negative return on equity of 121.26% and a negative net margin of 26.15%.The firm had revenue of $34.45 million for the quarter, compared to analysts’ expectations of $34.17 million.

Here are the key takeaways from Neuronetics’ conference call:

New CEO Dan Reuvers began a listening tour and outlined a strategy to broaden NeuroStar’s go-to-market, tighten clinic execution, and evaluate the business structure with an open mind to actions that could unlock shareholder value.
Q1 results: total revenue $34.5M (+8% YoY), NeuroStar revenue down 3% while system shipments rose 10% (34 systems), and Greenbrook clinic revenue up 15% driven by SPRAVATO; gross margin fell to 46.9% due to revenue mix, but adjusted EBITDA improved to -$6.6M.
Cash and liquidity tightened—total cash $19M (down from $34.1M), Q1 operating cash use $9.4M—management says current plan provides runway through the year but will continue evaluating the balance sheet and financing options.
Management is taking cost actions expected to deliver ~$2.5M–$3M of annualized savings (net benefits starting in Q3), improving collections and operational efficiency in clinics, and piloting expanded commercial models for NeuroStar to drive growth.
Company amended its debt (one‑time $5M principal payment to Perceptive) to reduce interest/covenant pressure and highlighted potential upside if Compass/psilocybin therapy is approved, though timing and reimbursement remain uncertain.

Neuronetics Trading Up 17.1%

NASDAQ:STIM traded up $0.35 during mid-day trading on Tuesday, reaching $2.37. 4,095,822 shares of the company’s stock traded hands, compared to its average volume of 2,136,144. Neuronetics has a 12-month low of $0.80 and a 12-month high of $4.85. The firm has a market capitalization of $164.56 million, a price-to-earnings ratio of -3.97 and a beta of 1.13. The company has a debt-to-equity ratio of 2.51, a current ratio of 2.02 and a quick ratio of 1.87. The company has a 50 day moving average price of $1.44 and a 200-day moving average price of $1.72.

Insider Transactions at Neuronetics

In related news, Director Keith J. Sullivan sold 46,289 shares of the business’s stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $1.34, for a total transaction of $62,027.26. Following the transaction, the director owned 1,590,924 shares in the company, valued at $2,131,838.16. The trade was a 2.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Jorey Chernett purchased 607,400 shares of Neuronetics stock in a transaction that occurred on Wednesday, March 18th. The shares were acquired at an average price of $1.35 per share, for a total transaction of $819,990.00. Following the acquisition, the insider owned 8,123,804 shares in the company, valued at $10,967,135.40. This trade represents a 8.08% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have purchased 1,857,872 shares of company stock worth $2,431,406 and have sold 183,032 shares worth $269,588. 8.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of STIM. Goldman Sachs Group Inc. increased its holdings in Neuronetics by 2,993.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 630,393 shares of the company’s stock valued at $2,320,000 after purchasing an additional 610,014 shares during the period. Geode Capital Management LLC boosted its position in Neuronetics by 172.3% during the 2nd quarter. Geode Capital Management LLC now owns 879,045 shares of the company’s stock valued at $3,068,000 after acquiring an additional 556,268 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Neuronetics by 195,023.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 66,342 shares of the company’s stock valued at $232,000 after acquiring an additional 66,308 shares in the last quarter. New York State Common Retirement Fund bought a new stake in Neuronetics during the 2nd quarter valued at approximately $103,000. Finally, Invesco Ltd. bought a new stake in Neuronetics during the 2nd quarter valued at approximately $100,000. Hedge funds and other institutional investors own 53.59% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on STIM shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Neuronetics in a research note on Thursday, January 22nd. Wall Street Zen raised Neuronetics from a “sell” rating to a “hold” rating in a research note on Saturday, April 18th. Finally, Canaccord Genuity Group reduced their price objective on Neuronetics from $7.00 to $3.00 and set a “buy” rating on the stock in a research note on Thursday, March 19th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $3.00.

Get Our Latest Stock Analysis on Neuronetics

About Neuronetics

(Get Free Report)

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.